ABSTRACT
Background: Dialysis treatment in chronic obstructive pulmonary disease (COPD) patients is a challenging setting: COPD frequently develop hypercapnia due to presence of CO2 that originates from the reaction between acetic/citric acid with bicarbonate, needed to prevent the precipitation of salts inside. Carbon dioxide passes through the dialysis membrane by diffusion, because of the significant difference in partial pressure between the dialysate compartment (80-100 mmHg) and the blood compartment (35-45 mmHg) thus determining CO2 overload. A COPD patient, on the other hand, may not be able to implement effective respiratory compensation mechanisms with the consequent onset of hypercapnia. Method(s): A 79-year-old ESRD patient was admitted because of SARS-CoV2 infection. His medical history was notable for emphysematous COPD with predominantly severe obstructive disorder on chronic oxygen therapy. The patient present acute hypercapnic dyspnea during the first dialysis session in COVID19 setting with severe desaturation episode associated with mixed acidosis (pH 7.13, pCO2 83 mmHg, HCO3- 22.7 mmol/l). The raise of pCO2 was remarkable, in fact partial pressure of CO2 (pCO2) was 61 mmHg before dialysis versus pCO2 83 mmHg after dialysis treatment (Fig.1). The patient appeared comatose and poorly responsive to stimuli. CPAP cycle was set up and he was placed in semi-orthopneic decubitus did not improve the clinical conditions. To prevent the hypercapnia condition Acetate Free Biofiltration (AFB) technique with profiled potassium (K+ 3.5 mmol/L) was prescribed. The vital parameters during this hemodialysis session remained stationary and the pCO2 values at the end of dialysis were comparable to those at the beginning of dialysis (pCO2 65 mmHg versus a.d. pCO2 63 mmHg) (Fig. 1). The following treatment were well tolerated with progressive improvement of respiratory parameters. Result(s): The AFB technique is characterized by a dialysate without buffers which do not react and do not produce carbon dioxide. The correction of the acid-base balance takes place with the post-dilution infusion of a sterile solution of sodium bicarbonate (NaHCO3). Furthermore, the absence of acetic acid avoids the stimulation of interleukin 1beta (IL-1beta) and of the Tumor Necrosis Factor alpha (TNFalpha) which in turn would have activated the enzyme Nitric Oxide Synthetase (iNOS) thus causing an increased production of Nitric Oxide (NO) and a consequent greater hemodynamic instability. AFB is therefore a more tolerated technique from a hemodynamic point of view. Conclusion(s): This case report has shown that AFB is an effective hemodialysis technique in preventing a condition of hypercapnia in patients suffering from respiratory diseases (Fig.2). The patient also experienced hemodynamic stability from the AFB with no longer presenting significant hypotensive episodes.
ABSTRACT
BACKGROUND AND AIMS: High flux haemodialysis membranes may modulate the cytokine storm of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but their impact in chronic haemodialysis (CHD) patients is not assessed [1, 2]. The aim of the study was the evaluation of asymmetric cellulose triacetate (ATA) and polymethylmethacrylate (PMMA) dialyzers on inflammatory markers in CHD patients with SARS-CoV-2. METHOD: A prospective, observational study on CHD patients (age ≥18 years) affected by SARS-CoV-2 was carried out. Patients were enrolled from March 2020 to May 2021 and dialysis was performed at S. Orsola University Hospital (Bologna, Italy) Dialysis Unit. Mechanical ventilation at diagnosis was exclusion criteria. Pre-and post-dialysis C-reactive protein (CRP), procalcitonin (PCT) and interleukin-6 (IL-6) were determined at each session and corrected for haemoconcentration during the complete SARS-CoV-2 period. Patients who underwent online haemodiafiltration (OLHDF) with PMMA dialyzer (Filtryzer BG-UTM, Toray, surface area 2.1 m2, cut-off 20 kDa, KUF 43 mL/h/mmHg) were compared with those who underwent OLHDF with ATA dialyzer (SolaceaTM, Nipro, surface area 2.1 m2, cut-off 45 kDa, KUF 72 mL/h/mmHg). The primary endpoint was to assess the differences in the reduction ratio/session (RR) of CRP, PCT and IL-6. RESULTS: A total of 74 patients were enrolled, 48 were treated with ATA and 26 were with PMMA (420 versus 191 dialysis sessions). The main results are shown in Table 1. Median IL-6RR% was higher for ATA [17.08%, interquartile range (IQR) -9.0 to 40.0 versus 2.95%, IQR -34.63 to 27.32]. CRP and PCT showed higher RR with ATA in comparison to PMMA. When IL-6RR > 25% was the dependent variable in the multiple logistic regression analysis only ATA showed a significant correlation [odds ratio (OR) 1.891, 95% confidence interval (95% CI) 1.273-2.840, P = .0018) while higher CRP favoured the risk of lower IL6RR (OR 0.9101, 95% CI 0.868-0.949, P < 0.0001) (Table 2). CONCLUSION: In SARS-CoV-2 CHD patients treated with OLHDF, ATA showed a better anti-inflammatory profile than PMMA, in particular regarding IL-6 RR.